<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097330</url>
  </required_header>
  <id_info>
    <org_study_id>CEASE-VT</org_study_id>
    <nct_id>NCT01097330</nct_id>
  </id_info>
  <brief_title>Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia</brief_title>
  <acronym>CEASE-VT</acronym>
  <official_title>Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia: A Multi-center Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Implantable Cardioverter Defibrillators (ICDs) provide a shock or pacing therapy to bring
      back a normal heart beat when a patient experiences a dangerous abnormal heart rhythm such as
      ventricular tachycardia (VT). ICDs are very successful in bringing back a normal heart beat
      when VT occurs, but they do not prevent further dangerous heart rhythms from occurring. This
      study is designed to determine the best way to manage patients who have an ICD and who
      continue to have episodes of VT. There are two methods for treatment the VT: 1) Ablation, and
      2) Medication.

      An ablation procedure involves placing a flexible catheter (insulated wire) in the groin area
      and threading it into the heart. After the doctor has located the affected area responsible
      for the VT, radiofrequency energy is delivered by the power generator through the catheter to
      the inside of the heart. The radiofrequency energy ablates (burns) a small area of the heart
      tissue thought to cause the VT.

      A medication called Amiodarone is an &quot;anti-arrhythmic&quot; prescribed to prevent abnormal heart
      rhythms from recurring.

      The purpose of this study is to compare these two different methods for treating VT.
      Treatment with ablation and amiodarone are both considered the standard of care for patients
      with VT but they have not been compared directly in a study like this before.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Anticipated non-feasibility of recruitment objectives
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome-time to first occurrence of any of: 1. Appropriate ICD Therapy 2. Slow VT below ICD detection threshold leading to hospitalization or necessitates antiarrhythmics and/or ablation 3. Sudden Cardiac Death</measure>
    <time_frame>follow-up visits every 3 months until a common, event-driven study end date (up to 48 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>composite of: a. Ablation or amiodarone complications b. Inappropriate shocks from ICD c. Need for concomitant use of sotalol, dofetilide, azimilide or class I antiarrhythmic agents in either arm of the trial</measure>
    <time_frame>follow-up visits every 3 months until a common, event-driven study end date (up to 48 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score in each treatment arm using the EQ-5D questionnaire</measure>
    <time_frame>at one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Defibrillators, Implantable</condition>
  <condition>Tachycardia, Ventricular</condition>
  <arm_group>
    <arm_group_label>Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter based radiofrequency ablation for ischemic ventricular tachycardia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiodarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <description>Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization</description>
    <arm_group_label>Ablation</arm_group_label>
    <other_name>VT ablation</other_name>
    <other_name>ischemic VT ablation</other_name>
    <other_name>catheter ablation</other_name>
    <other_name>radiofrequency ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study</description>
    <arm_group_label>Amiodarone</arm_group_label>
    <other_name>Cordarone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - Patients must meet all of the following criteria:

          -  &gt; 18 and &lt; 85 years of age

          -  ICD implanted for primary prophylaxis against sudden cardiac death or ICD implanted
             for secondary prophylaxis against spontaneous or inducible sustained VT without any
             reversible causes

          -  CAD with prior MI

          -  ICD or ECG documentation of ventricular arrhythmia responsible for appropriate ICD
             therapy [ATP &amp; shocks].

        Exclusion Criteria - Patients should not have any of the following criteria:

          -  Contraindication or allergy to contrast media, routine procedural medications or
             catheter materials

          -  Contraindication to an interventional procedure

          -  Current or previous (within 3 months) amiodarone therapy

          -  Atrial Fibrillation requiring antiarrhythmic drug therapy

          -  Contraindication to amiodarone therapy

          -  New York Heart Association (NYHA) functional class IV

          -  Myocardial infarction within the past 60 days

          -  Stroke within the past 90 days

          -  Unstable angina

          -  Hypertrophic cardiomyopathy, Non-ischemic dilated cardiomyopathy, Arrhythmogenic Right
             Ventricular Dysplasia, Brugada Syndrome, Catecholamine sensitive polymorphic VT or
             long QT syndrome

          -  Patients with active ischemia that are eligible for revascularization

          -  Life expectancy less than 6 months

          -  Incessant or multiple episodes of VT requiring immediate therapy with medications or
             ablation

          -  Untreated hypothyroidism or hyperthyroidism. Patients who are euthyroid on thyroid
             hormone replacement therapy are acceptable.

          -  Current enrollment in another investigational drug or device study.

          -  Presence of any other condition that the investigator feels would be problematic or
             would restrict or limit the participation of the patient for the entire study period.

          -  Absolute contra-indication to the use of heparin and or warfarin.

          -  Documented intra-atrial thrombus, ventricular thrombus (&lt; 6 months after detection of
             thrombus), tumor, or another abnormality which precludes catheter introduction.

          -  Females of childbearing potential who are not practicing protocol acceptable method of
             birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Natale, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Cardiac Arrhythmia Research Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David J Callans, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos A. Morillo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute, McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Girish M. Nair, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute, McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et Pneumologie de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijng Fuwai Heart Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.phri.ca/</url>
    <description>Population Health Research Institute</description>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Carlos Morillo</name_title>
    <organization>Population Health Research Institute</organization>
  </responsible_party>
  <keyword>Defibrillators, Implantable</keyword>
  <keyword>Tachycardia, Ventricular</keyword>
  <keyword>Catheter Ablation</keyword>
  <keyword>Amiodarone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 30, 2015</submitted>
    <returned>February 2, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

